BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer
Bergen, Norway, Sep 28 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, is pleased to announce that the Company will present three ongoing lung cancer clinical trials with BGB324 at the 18th World Conference on Lung Cancer in Yokohama, Japan, October 15 – 18, 2017.The three presentations will show clinical results to date and discuss the rationale of the clinical studies undertaken with BGB324, BerGenBio’s lead candidate, a first-in-class and highly